179 related articles for article (PubMed ID: 34696258)
1. Pentavalent Disabled Infectious Single Animal (DISA)/DIVA Vaccine Provides Protection in Sheep and Cattle against Different Serotypes of Bluetongue Virus.
van Rijn PA; Maris-Veldhuis MA; Spedicato M; Savini G; van Gennip RGP
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696258
[TBL] [Abstract][Full Text] [Related]
2. The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.
van Rijn PA; Maris-Veldhuis MA; van Gennip RGP
Viruses; 2021 May; 13(5):. PubMed ID: 34067226
[TBL] [Abstract][Full Text] [Related]
3. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
[TBL] [Abstract][Full Text] [Related]
4. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
Feenstra F; Pap JS; van Rijn PA
Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
[TBL] [Abstract][Full Text] [Related]
5. Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue.
Tacken MGJ; Daus FJ; Feenstra F; van Gennip RGP; van Rijn PA
Vaccine; 2015 Oct; 33(42):5539-5545. PubMed ID: 26387435
[TBL] [Abstract][Full Text] [Related]
6. Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep.
van Rijn PA; Daus FJ; Maris-Veldhuis MA; Feenstra F; van Gennip RGP
Vaccine; 2017 Jan; 35(2):231-237. PubMed ID: 27916409
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
[TBL] [Abstract][Full Text] [Related]
8. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
[TBL] [Abstract][Full Text] [Related]
9. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
[TBL] [Abstract][Full Text] [Related]
10. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
[TBL] [Abstract][Full Text] [Related]
11. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
[TBL] [Abstract][Full Text] [Related]
12. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
[TBL] [Abstract][Full Text] [Related]
13. An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.
Saminathan M; Singh KP; Khorajiya JH; Dinesh M; Vineetha S; Maity M; Rahman AF; Misri J; Malik YS; Gupta VK; Singh RK; Dhama K
Vet Q; 2020 Dec; 40(1):258-321. PubMed ID: 33003985
[TBL] [Abstract][Full Text] [Related]
14. Non-structural protein NS3/NS3a is required for propagation of bluetongue virus in Culicoides sonorensis.
Feenstra F; Drolet BS; Boonstra J; van Rijn PA
Parasit Vectors; 2015 Sep; 8():476. PubMed ID: 26383094
[TBL] [Abstract][Full Text] [Related]
15. Bluetongue vaccines: the past, present and future.
Bhanuprakash V; Indrani BK; Hosamani M; Balamurugan V; Singh RK
Expert Rev Vaccines; 2009 Feb; 8(2):191-204. PubMed ID: 19196199
[TBL] [Abstract][Full Text] [Related]
16. Vaccines against bluetongue in Europe.
Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
[TBL] [Abstract][Full Text] [Related]
17. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
[TBL] [Abstract][Full Text] [Related]
18. Prospects of Next-Generation Vaccines for Bluetongue.
van Rijn PA
Front Vet Sci; 2019; 6():407. PubMed ID: 31824966
[TBL] [Abstract][Full Text] [Related]
19. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
Kochinger S; Renevey N; Hofmann MA; Zimmer G
Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
[TBL] [Abstract][Full Text] [Related]
20. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep.
Pérez de Diego AC; Athmaram TN; Stewart M; Rodríguez-Sánchez B; Sánchez-Vizcaíno JM; Noad R; Roy P
PLoS One; 2011; 6(10):e26666. PubMed ID: 22046324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
